Get Coronavirus Updates Now
NMDOH Logo

2019 Novel Coronavirus Disease (COVID-19)

Resources


CDC 2019 Novel Coronavirus Risk Assesment Summary

CDC 2019 Novel Coronavirus Risk Assesment Summary

CDC 2019 Novel Coronavirus Risk Assesment Summary

Outbreaks of novel virus infections among people are always of public health concern. The risk from these outbreaks depends on characteristics of the virus, including how well it spreads between people, the severity of resulting illness, and the medical or other measures available to control the impact of the virus (for example, vaccine or treatment medications).

CDC Confirmed 2019-nCoV Cases Globally

CDC Confirmed 2019-nCoV Cases Globally

CDC Confirmed 2019-nCoV Cases Globally

Locations with Confirmed 2019-nCoV Cases

CDC Guidance for Travelers

CDC Guidance for Travelers

CDC Guidance for Travelers

CDC Guidance for Travelers

CDC Interim Guidance for Businesses and Employers

CDC Interim Guidance for Businesses and Employers

CDC Interim Guidance for Businesses and Employers

This interim guidance is based on what is currently known about the Coronavirus Disease 2019 (COVID-19). The Centers for Disease Control and Prevention (CDC) will update this interim guidance as needed and as additional information becomes available.

CDC Interim Guidance for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation (PUIs) for 2019 Novel Coronavirus

CDC Interim Guidance for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation (PUIs) for 2019 Novel Coronavirus

CDC Interim Guidance for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation (PUIs) for 2019 Novel Coronavirus

Health care providers should contact their local/state health department immediately to notify them of patients with fever and lower respiratory illness who traveled to Wuhan, China within 14 days of symptom onset. Local and state public health staff will determine if the patient meets the criteria for a patient under investigation (PUI) for 2019 Novel Coronavirus (2019-nCoV).

CDC Interim Guidance for Emergency Medical Services (EMS) Systems

CDC Interim Guidance for Emergency Medical Services (EMS) Systems

CDC Interim Guidance for Emergency Medical Services (EMS) Systems

This guidance applies to all first responders, including law enforcement, fire services, emergency medical services, and emergency management officials, who anticipate close contact with persons with confirmed or possible COVID-19 in the course of their work.

CDC Interim Guidance for Healthcare Infection Prevention and Control

CDC Interim Guidance for Healthcare Infection Prevention and Control

CDC Interim Guidance for Healthcare Infection Prevention and Control

Infection control procedures including administrative rules and engineering controls, environmental hygiene, correct work practices, and appropriate use of personal protective equipment (PPE) are all necessary to prevent infections from spreading during healthcare delivery.

CDC Interim Guidance for Healthcare Professionals

CDC Interim Guidance for Healthcare Professionals

CDC Interim Guidance for Healthcare Professionals

Limited information is available to characterize the spectrum of clinical illness associated with 2019-nCoV. No vaccine or specific treatment for 2019-nCoV infection is available; care is supportive.

CDC Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus

CDC Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus

CDC Interim Guidance for Implementing Home Care of People Not Requiring Hospitalization for 2019 Novel Coronavirus

This interim guidance is for staff at local and state health departments, infection prevention and control professionals, and healthcare personnel who are coordinating the home care and isolation of people with confirmed or suspected 2019-nCoV infection, including patients under investigation.

CDC Interim Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus Exposure in Travel-associated or Community Settings

CDC Interim Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus Exposure in Travel-associated or Community Settings

CDC Interim Guidance for Risk Assessment and Public Health Management of Persons with Potential 2019 Novel Coronavirus Exposure in Travel-associated or Community Settings

This interim guidance is effective as of February 3, 2020, and does not apply retrospectively to people who have been in China during the previous 14 days and are already in the United States.

CDC Interim Laboratory Biosafety Guidelines for Handing and Processing Specimens Associated with 2019 Novel Coronavirus

CDC Interim Laboratory Biosafety Guidelines for Handing and Processing Specimens Associated with 2019 Novel Coronavirus

CDC Interim Laboratory Biosafety Guidelines for Handing and Processing Specimens Associated with 2019 Novel Coronavirus

To date, we do not fully understand the pathogenic potential and transmission dynamics of 2019 Novel Coronavirus (2019-nCoV). Until more information becomes available, precautions should be taken in collecting and handling specimens that may contain 2019-nCoV.

Department of Health’s COVID-19 Site

Department of Health’s COVID-19 Site

Department of Health’s COVID-19 Site

The DOH COVID-19 site provides the latest information and executive orders regarding the COVID-19 outbreak.